CFTR modulators for the treatment of cystic fibrosis
RS Pettit, C Fellner - Pharmacy and Therapeutics, 2014 - pmc.ncbi.nlm.nih.gov
RS Pettit, C Fellner
Pharmacy and Therapeutics, 2014•pmc.ncbi.nlm.nih.govCFTR Modulators for the Treatment of Cystic Fibrosis - PMC Skip to main content Here's how
you know Official websites use .gov A .gov website belongs to an official government
organization in the United States. Secure .gov websites use HTTPS A lock ( Locked padlock
icon ) or https:// means you've safely connected to the .gov website. Share sensitive information
only on official, secure websites. NCBI home page Search Log in Dashboard Publications
Account settings Log out Search… Search NCBI Primary site navigation Close Search Search …
you know Official websites use .gov A .gov website belongs to an official government
organization in the United States. Secure .gov websites use HTTPS A lock ( Locked padlock
icon ) or https:// means you've safely connected to the .gov website. Share sensitive information
only on official, secure websites. NCBI home page Search Log in Dashboard Publications
Account settings Log out Search… Search NCBI Primary site navigation Close Search Search …
Defects in a single gene lead to the defective proteins that cause cystic fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, others are in development.
pmc.ncbi.nlm.nih.gov
